Eli Lilly (LLY)

State Street's fund charges just 0.08% annually versus 0.38% for iShares, but the broader portfolio offers 100 holdings versus 60.

State Street's concentrated 60-stock approach outpaced Fidelity's broader 365-holding fund over five years, though both charge identical 0.08% fees.

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits...

PINK outperformed XLV by 8.7 percentage points over one year, but carries higher fees and volatility. XLV offers lower costs and a higher dividend yield for passive healthcare exposure.

Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk.

PPH targets drugmakers exclusively with higher returns but steeper costs, while XLV diversifies across medical equipment and providers at a fraction of the fee.

How diversified is a 147-stock fund when 10 names hold 60% of the money?

As AI-related stocks weaken, new leaders emerge.

Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.

There are plenty of reasons to love these companies.

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.

VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The choice comes down to whether to lean into pharma-driven returns or take a broader approach to global healthcare.

IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost.

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure.

A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.